计算溶液所需的质量、体积或浓度。
,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3) , with IC 50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively
In Vitro
CPL304110 (0-0.6 μM) dose-dependently inhibits FGFR2 phosphorylation and downstream signaling (p-ERK). CPL304110 (compound 56q) exhibits in SNU-16 proliferation assay with an IC 50 of 85.64 nM. CPL304110 (compound 56q) demonstrats a more than 45-fold, 345-fold, 395-fold and 680-fold selectivity over KDR (VEGFR2), Flt3, Aura A and PDGFRb, respectively relative to FGFR2, and no significant inhibitory effects were observed with other tyrosine kinases. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: SNU-16 cell lines. Concentration: 0-0.6 μM. Incubation Time: 1 h. Result: Suppressed FGFR2 phosphorylation and downstream signaling (p-ERK)
In Vivo
CPL304110 (p.o., 40 mg/kg) exhibits a t 1/2 of 2 h and C max of 3369 ng/mL in mice . CPL304110 (compound 56q, 2 X 20 mg/kg) significantly inhibits tumor growth in mice without significant body loss or any toxicity. On day 21 (D21, day of termination) the tumor growth inhibition (TGI) is 64% for dosing 20 mg/kg twice a day . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Severe combined immunodeficient (SCID) mice implanted subcutaneously with SNU-16 (human) . Dosage: 20 mg/kg (X2). Administration: Orally, twice daily for 21 days. Result: After 6 hours of last dosing, concentration of 56q decreased in the plasma (9%) but increased stepwise in the tumor cells (121%).
IC50& Target:FGFR1 0.75 nM (IC 50 ) FGFR2 0.5 nM (IC 50 ) FGFR3 3.05 nM (IC 50 )